Fig. 5: The oncometabolite R-2HG exacerbates the maladaptive effects of doxorubicin in human iPS-derived cardiomyocytes. | Leukemia

Fig. 5: The oncometabolite R-2HG exacerbates the maladaptive effects of doxorubicin in human iPS-derived cardiomyocytes.

From: IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis

Fig. 5

Representative images for sarcomere organization in human iPS-derived CMs immunostained for α-actinin and exposed to doxorubicin 1 µM and/ or R-2HG 20 mM (a) assessed using a semiquantitative grading system (Scale bar 100 µm). (b) Gene-Ontology (Biological Process) analysis showing the functional categories and the identity of enriched upregulated (c) or downregulated genes (d) with corresponding heat maps after R-2HG exposure in doxorubicin treated human iPS-derived CMs from the RNA sequencing experiment.

Back to article page